Sanofi (EPA:SAN) has been assigned an average rating of “Hold” from the sixteen ratings firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, ten have given a hold rating and five have issued a buy rating on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is €87.69 ($104.39).
Several research analysts have recently weighed in on SAN shares. Morgan Stanley set a €92.00 ($109.52) target price on Sanofi and gave the stock a “buy” rating in a report on Friday, October 6th. Goldman Sachs Group set a €82.00 ($97.62) target price on Sanofi and gave the stock a “neutral” rating in a report on Friday, November 3rd. Jefferies Group set a €90.00 ($107.14) target price on Sanofi and gave the stock a “neutral” rating in a report on Monday, October 16th. BNP Paribas set a €85.00 ($101.19) target price on Sanofi and gave the stock a “neutral” rating in a report on Tuesday, September 12th. Finally, set a €78.00 ($92.86) target price on Sanofi and gave the stock a “neutral” rating in a report on Friday, November 3rd.
Sanofi (EPA SAN) traded down €0.03 ($0.04) during mid-day trading on Thursday, reaching €73.18 ($87.12). The company had a trading volume of 2,320,000 shares, compared to its average volume of 2,250,000. Sanofi has a 12 month low of €72.63 ($86.46) and a 12 month high of €92.97 ($110.68).
ILLEGAL ACTIVITY WARNING: “Sanofi (SAN) Receives €87.69 Consensus Target Price from Analysts” was first reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://transcriptdaily.com/2017/12/11/sanofi-san-receives-87-69-consensus-target-price-from-analysts.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.